(Effects)
Line 1: Line 1:
Dissociative anesthetic that is roughly 10 times stronger than 4-MeO-PCP. May also have opioid or dopaminergic activity.
+
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
  
 +
The effects are often described as more euphoric and mentally clearer than many related compounds.
  
 
= History =
 
= History =
  
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
+
A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
  
= Dosage =  
+
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
Oral Threshold: 1.5-3 mg Light: 3-5mg Common: 5-8mg Strong: 8-12mg  Heavy: 12mg+
+
 
 +
= Dosage =
 +
 
 +
Use a precise milligram scale to avoid overdosing.
 +
 
 +
{| class="wikitable"
 +
 
 +
|+ Oral
 +
 
 +
|-
 +
 
 +
| Threshold || 1.5-3 mg
 +
 
 +
|-
 +
 
 +
| Light || 3-5 mg
 +
 
 +
|-
 +
 
 +
| Common || 5-8 mg
 +
 
 +
|-
 +
 
 +
| Strong || 8-12 mg
 +
 
 +
|}
  
 
= Duration =
 
= Duration =
Oral Onset: 20-40 minutes.
 
  
Insufflated Onset: 5-15 minutes
+
{| class="wikitable"
  
Duration for oral and insufflated: 3-5 hours +/- 1 hour depending on dose.
+
|+ Oral
  
After-effects: 2-48 hours.  
+
|-
 +
 
 +
| Onset || 20-40 minutes
 +
 
 +
|-
 +
 
 +
| Total || 4-6 hours
 +
 
 +
|-
 +
 
 +
| After-effects || 2-48 hours
 +
 
 +
|}
 +
 
 +
Insufflated onset is approximately 5-15 minutes and the duration is a bit shorter.
 +
 
 +
= Effects =
 +
 
 +
== Postive ==
 +
 
 +
* Increase in energy / stimulation
 +
 
 +
* Euphoria
 +
 
 +
* Pleasant mental and/or body high
  
= Effects =
 
* Dissociation from reality
 
* Difficulty walking
 
* Difficulty talking
 
* Time dilation
 
 
* Music appreciation
 
* Music appreciation
* May get stuck in thought loops
 
* Produces an inner stillness as if all the leaky naggings of the subconscious are completely muted
 
  
= Harm Reduction =
+
* Disconnected thoughts
  
Do not drive or operate heavy machinery. Take extra precaution if going out in public on 3-MeO-PCP.  Do not drink alcohol or take any other drugs.
+
* Sense of calm
  
= Chemistry and Pharmacology =
+
* Increased sociability, loss of inhibitions
  
3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. 3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor
+
* Closed- and open-eye visuals
  
= Legal =
+
* Shifts in perception of reality
  
May be Class B in UK as an analog of MXE.
+
== Neutral ==
  
May be illegal in the US as part of the Analog Act.
+
* Increased heart rate (lower doses)
  
= Sites =
+
* Altered time perception
  
[http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2 Interview with a 3-MeO Chemist]
+
* Disrupted speech patterns
  
[http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract From MXE to PCP]
+
* Analgesia (decreased pain awareness) and numbness
  
 +
* Distorted sensory perceptions, hallucinations
 +
 +
* Unusual and unpredictable behavior
 +
 +
* Mild to moderate dissociation
 +
 +
* Confusion, disorientation
 +
 +
== Negative ==
 +
 +
* Disturbing hallucinations and/or delusions
 +
 +
* Anxiety, paranoia
 +
 +
* Severe dissociation, depersonalization
 +
 +
* Ataxia (loss of motor coordination)
 +
 +
* Psychotic episodes
 +
 +
* Nausea, vomiting
 +
 +
* Temporary amnesia
 +
 +
* Severe distortion or loss of auditory/visual perception
 +
 +
= Harm Reduction =
 +
 +
Do not drive or operate heavy machinery. Take extra precaution if going out in public on 3-MeO-PCP.
 +
 +
== WARNING ==
 +
 +
We recommend to have a sober friend with you when taking this substance for the first time.
 +
 +
== Interactions ==
 +
 +
Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.
 +
 +
Specifically, do not mix with alcohol or benzodiazepines.
 +
 +
= Chemistry and Pharmacology =
 +
 +
3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
 +
 +
3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.
 +
 +
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.
 +
 +
= Legal status=
 +
 +
UK: Class B, as are all arylcyclohexamines.
 +
 +
US: Covered by the analogue act if sold for human consumption.
 +
 +
= Links =
 +
 +
[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
 +
 +
[http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist]
 +
 +
[http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract From MXE to PCP]
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
 +
 
[[Category:Dissociative]]
 
[[Category:Dissociative]]

Revision as of 18:49, 21 July 2014

3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.

The effects are often described as more euphoric and mentally clearer than many related compounds.

History

A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.

Dosage

Use a precise milligram scale to avoid overdosing.

Oral
Threshold 1.5-3 mg
Light 3-5 mg
Common 5-8 mg
Strong 8-12 mg

Duration

Oral
Onset 20-40 minutes
Total 4-6 hours
After-effects 2-48 hours

Insufflated onset is approximately 5-15 minutes and the duration is a bit shorter.

Effects

Postive

  • Increase in energy / stimulation
  • Euphoria
  • Pleasant mental and/or body high
  • Music appreciation
  • Disconnected thoughts
  • Sense of calm
  • Increased sociability, loss of inhibitions
  • Closed- and open-eye visuals
  • Shifts in perception of reality

Neutral

  • Increased heart rate (lower doses)
  • Altered time perception
  • Disrupted speech patterns
  • Analgesia (decreased pain awareness) and numbness
  • Distorted sensory perceptions, hallucinations
  • Unusual and unpredictable behavior
  • Mild to moderate dissociation
  • Confusion, disorientation

Negative

  • Disturbing hallucinations and/or delusions
  • Anxiety, paranoia
  • Severe dissociation, depersonalization
  • AtaxiaLoss of motor coordination (loss of motor coordination)
  • Psychotic episodes
  • Nausea, vomiting
  • Temporary amnesia
  • Severe distortion or loss of auditory/visual perception

Harm Reduction

Do not drive or operate heavy machinery. Take extra precaution if going out in public on 3-MeO-PCP.

WARNING

We recommend to have a sober friend with you when taking this substance for the first time.

Interactions

Check out our Drug Combinations page and chart for interactions and combinations of common drugs.

Specifically, do not mix with alcohol or benzodiazepines.

Chemistry and Pharmacology

3-MeO-PCP binds to the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Reuptake Inhibitor (SRISerotonin Reuptake Inhibitor).

3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.

3-MeO-PCP has a Ki of 20 nM for the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor, 216 nM for the serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. transporter and 42 for the sigma1 receptor.

Legal status

UK: Class B, as are all arylcyclohexamines.

US: Covered by the analogue act if sold for human consumption.

Links

Wikipedia

Interview with a Ketamine Chemist

From MXE to PCP

Top Contributors